Role of Consolidative Stereotactic Body Radiation Therapy in Oligoresistant/Oligoprogressive Pulmonary Parenchymal Metastases.

Aim: To extend the survival of patients by providing local control of metastases in oligoresistance/oligoprogressive disease.

Methods: We retrospectively evaluated the efficacy of stereotactic body radiotherapy (SBRT) applied to 30 lesions in the lungs of 19 patients who were considered inoperable by the tumor board upon the development of oligoresistance/oligoprogressive lung metastasis while undergoing chemotherapy between January 2016 and December 2017. Each patient had one to five metastases in their lungs. The median SBRT biologic effective dose at α/β of 10 (BED10 ) was 180.0 (IQR: 115.5-180.0) Gy.

Results: We obtained effective, low-toxicity results. The rates of local control were 89.4%, 84.2%, and 78.9% for the 1st, 2nd, and 3rd years, respectively. The median local control time was 4 (IQR: 3-6) months. The median overall survival (OS) was 36.3 (IQR: 29.7-42.9) months. The rates of OS for the 1st, 2nd, and 3rd years were 89.5%, 73.7%, and 61.4%, respectively. Despite the nonoccurrence of grade 4-5 toxicity in the lungs, six (31.6%) patients had grade 1-3 pulmonary pneumonia, one patient had a grade 4 skin ulceration, and two patients had increased chronic obstructive pulmonary disease in the follow-up period.

Discussion: In patients with oligometastatic lung tumors, SBRT is very effective in terms of progression-free survival and OS.